Grant of Share Options

Destiny Pharma PLC

12 May 2023

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of Share Options

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it has granted options over a total of 431,354 new ordinary shares of £0.01 each in the Company ("Options") (representing 0.45 per cent. of the Company's issued share capital) to certain employees of the Company, including the Directors and PDMR named below.

Name	Position	Deferred Bonus Options issued Under 2020 LTIP Scheme*	Total Options held post issue	Options held as a percentage of issued share capital	Ordinary Shares held	Ordinary Shares held as a percentage  of issued share capital
Neil Clark	Chief Executive Officer	52,264	1,424,798	1.50%	117,033	0.12%
Shaun Claydon	Chief Financial Officer	47,100	911,001	0.96%	24,286	0.03%
William Love**	Chief Scientific Officer	43,313	959,549	1.01%	6,509,500	6.83%
Yuri Martina	Chief Medical Officer	71,177	261,177	0.27%	-	-

*  granted in respect of bonuses due for the financial year ended 31 December 2022

**3,317,700 of these Ordinary Shares are held by William Love and 3,191,800 are held by Carol Love 

The above options granted to the Directors and PDMR represent awards granted under the Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options (the "Employee LTIP 2020"). The above options granted to the Directors and PDMR have been granted with a nominal exercise price, will vest on 1 February 2025 and are exercisable up to 10 years from the date of grant. Including the grant of these Options, the Company will have outstanding options over approximately 8.72 per cent. of its issued share capital.  

For further information, please contact: 

Destiny Pharma plc 

Neil Clark, CEO 

Shaun Claydon, CFO 

[phone] 

[e-mail] 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

Optimum Strategic Communications 

Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper

[phone]

[e-mail] 

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV^TM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the Company, please visit  https://www.destinypharma.com      

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Neil Clark
2.	Reason for the Notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share  52,264 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	12 May 2023
f)	Place of the transaction	Outside of trading venue

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Shaun Claydon
2.	Reason for the Notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 47,100 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	12 May 2023
f)	Place of the transaction	Outside of trading venue

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	William Love
2.	Reason for the Notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") under the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 43,313 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	12 May 2023
f)	Place of the transaction	Outside of trading venue

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Yuri Martina
2.	Reason for the Notification
a)	Position/status	Chief Medical Officer
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Grant of award of options over ordinary shares of 1 pence each ("Ordinary Shares") the 2020 Destiny Pharma plc Long Term Incentive Plan.
	Identification code	DEST      GB00BDHSP575
b)	Nature of the transaction	Grant of award of options over Ordinary Shares under the 2020 Destiny Pharma plc Long Term Incentive Plan.
c)	Price(s) and volume(s)	1 pence exercise price per Ordinary Share 71,177 Ordinary Shares
d)	Aggregated information: Aggregated volume Price	See 4c) above
e)	Date of the transaction	12 May 2023
f)	Place of the transaction	Outside of trading venue

 

END